SCHEMBL6474502

SCHEMBL6474502

CCCS(=O)(=O)NCC(C)Oc1ccc(-c2cccc(-c3cccs3)c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 2/20 0.42
PPARG P37231 2/20 0.38
PPARA Q07869 2/20 0.38
GRIA4 P48058 1/20 0.37
PRMT6 Q96LA8 1/20 0.36
CA12 O43570 1/20 0.36
CA2 P00918 1/20 0.36
HDAC2 Q92769 3/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SDHB P21912 2/20 0.35
HDAC3 O15379 2/20 0.35
HDAC1 Q13547 2/20 0.35
MTNR1A P48039 2/20 0.34
MTNR1B P49286 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6474062 0.95 PSMB5 (0.43) PSMB5PPARGPPARAGRIA4CA12
SCHEMBL6474497 0.86 GRIA4 (0.43) PSMB5PPARGPPARAGRIA4PRMT6
SCHEMBL6474047 0.83 PPARG (0.44) PPARGPPARAGRIA4CA12CA2
SCHEMBL6475297 0.82 GRIA4 (0.48) PPARGPPARAGRIA4MAPTSMN1; SMN2
SCHEMBL6482324 0.82 GRIA4 (0.46) GRIA4CA12CA2KDM4EMAPT
SCHEMBL6479543 0.82 GRIA4 (0.45) GRIA4MAPTMTNR1AMTNR1B
SCHEMBL6474430 0.82 PLAU (0.40) GRIA4CA12CA2MAPTMTNR1A
SCHEMBL6474263 0.82 GRIA4 (0.40) GRIA4KMT2AMTNR1AMTNR1B
SCHEMBL6474219 0.82 MTNR1A (0.50) GRIA4KDM4EMTNR1AMTNR1B
SCHEMBL6475469 0.81 PLAU (0.43) GRIA4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US claimed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
EP-1390072-A2 USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES ELI LILLY AND COMPANY (US) 2004-02-25 EP disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed
WO-2002089848-A2 USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES ELI LILLY AND COMPANY (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 PSMB5 1605/4885PPARG 828/4885PPARA 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.